Patents by Inventor Valentina Mainero
Valentina Mainero has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190209472Abstract: Topical formulations to treat skin conditions, such as psoriasis, are provided in which a polymer conjugate of an indolocarbazole exhibits reduced systemic exposure. An example formulation includes the TrkA antagonist, SNA-120, together with a preservative/antioxidant, a preservative/solvent, a solvent, a solvent/moisturizing agent, a stiffening agent, and one or more emollients/emulsifying agents.Type: ApplicationFiled: December 3, 2018Publication date: July 11, 2019Inventors: Valentina Mainero, Silvio Traversa
-
Publication number: 20170304398Abstract: The present invention relates to novel polymer conjugates of polypeptide variants of the HMGB1 high affinity binding domain Box-A (HMGB1 Box-A) or of a biologically active fragment of HMGB1 Box-A. Further, the invention relates to novel polymer conjugates of polypeptide variants of the HMGB1 high affinity binding domain Box-A (HMGB1 Box-A). Moreover, the present invention concerns the use of said polymer conjugates of polypeptide molecules of HMGB1 Box-A to diagnose, prevent, alleviate and/or treat pathologies associated with extracellular HMGB1 and/or associated with an increased expression of RAGE.Type: ApplicationFiled: April 28, 2017Publication date: October 26, 2017Applicant: Creabilis Therapeutics S.P.A.Inventors: Silvio TRAVERSA, Chiara LORENZETTO, Valentina MAINERO, Sebastiano MORENA, Silvano FUMERO, Luca BECCARIA
-
Patent number: 9707298Abstract: The present invention relates to novel polymer conjugates of polypeptide variants of the HMGB1 high affinity binding domain Box-A (HMGB1 Box-A) or of a biologically active fragment of HMGB1 Box-A. Further, the invention relates to novel polymer conjugates of polypeptide variants of the HMGB1 high affinity binding domain Box-A (HMGB1 Box-A). Moreover, the present invention concerns the use of said polymer conjugates of polypeptide molecules of HMGB1 Box-A to diagnose, prevent, alleviate and/or treat pathologies associated with extracellular HMGB1 and/or associated with an increased expression of RAGE.Type: GrantFiled: December 27, 2012Date of Patent: July 18, 2017Assignee: CREABILIS THERAPEUTICS S.R.L.Inventors: Silvio Traversa, Chiara Lorenzetto, Valentina Mainero, Sebastiano Morena, Silvano Fumero, Luca Beccaria
-
Patent number: 8961927Abstract: The invention provides MRI detectable species of formula (I) Dp-Sn-Nm??(I) wherein D is a MRI detectable moiety S is a spacer N is a molecule of a nutrient or pseudo-nutrient n is 0 or an integer m is an integer and p is an integer. These compounds are useful for internalizing into tumor cells an amount of the MRI detectable moiety that is distinguishably higher than the amount internalized in normal healthy cells thus allowing the diagnosis of tumors. The internalization of the MRI detectable moiety involves the nutrients or pseudo-nutrients transporting system. Preferred compounds of formula (I) are those wherein D is the chelated complex of a paramagnetic metal ion.Type: GrantFiled: July 2, 2010Date of Patent: February 24, 2015Assignee: Bracco Imaging S.p.A.Inventors: Silvio Aime, Valentina Mainero, Simonetta Chirich Geninatti, Claudia Cabella
-
Patent number: 8926955Abstract: The present invention relates to a process for the preparation of polymer conjugates of indolocarbaxole compounds, in particular of polymer conjugates of K-252a and derivatives thereof, by a synthetic route which results in a highly pure product, with a high product yield. In a further aspect the present invention relates to novel polymer conjugates of K-252a and derivatives thereof, wherein the chemical group linking the polymer unity to the K-252a or to the K-252a derivative compound is characterized by a 5-member oxazolidindionic cyclic structure. These novel polymer conjugates are obtained through the novel synthetic route with high purity and high yields.Type: GrantFiled: December 22, 2009Date of Patent: January 6, 2015Assignee: Creabilis S.A.Inventors: Raffaella Bagnod, Luca Beccaria, Luisa Bertarione Rava Rossa, Domenico Criscuolo, Chiara Lorenzetto, Valentina Mainero, Alessandra Marconi, Carlo Pincelli, Silvio Traversa
-
Patent number: 8673347Abstract: The present invention relates to novel polymer conjugates of K-252a and derivatives thereof and to their use for the preparation of a pharmaceutical composition useful for the prevention, alleviation and treatment of kinase-associated pathologies. In particular, the present invention relates to the prevention, alleviation and treatment of HMGB1-associated pathologies. The invention relates to the use of the novel polymer conjugates of K-252a and derivatives thereof in the preparation of a pharmaceutical composition useful for the prevention, alleviation and treatment of a) neurological disorders, neuropathies and neurodegenerative disorders of the central and peripheral nervous system; b) dermal pathologies, in particular dermal pathologies associated with an excessive keratinocyte proliferation, in particular psoriasis; and c) NGF-related pain.Type: GrantFiled: August 25, 2006Date of Patent: March 18, 2014Assignee: Creabilis Therapeutics S.p.A.Inventors: Silvio Traversa, Raffaella Bagnod, Domenico Barone, Luisa Bertarione Rava Rossa, Silvano Fumero, Valentina Mainero, Alessandra Marconi, Cecilia Oderda, Carlo Pincelli, Chiara Lorenzetto, Luca Beccaria
-
Publication number: 20140065094Abstract: The present invention relates to novel polymer conjugates of polypeptide variants of the HMGB1 high affinity binding domain Box-A (HMGB1 Box-A) or of a biologically active fragment of HMGB1 Box-A. Further, the invention relates to novel polymer conjugates of polypeptide variants of the HMGB1 high affinity binding domain Box-A (HMGB1 Box-A). Moreover, the present invention concerns the use of said polymer conjugates of polypeptide molecules of HMGB1 Box-A to diagnose, prevent, alleviate and/or treat pathologies associated with extracellular HMGB1 and/or associated with an increased expression of RAGE.Type: ApplicationFiled: December 27, 2012Publication date: March 6, 2014Applicant: Creabillis Therapeutics S.P.A.Inventors: Silvio TRAVERSA, Chiara LORENZETTO, Valentina MAINERO, Sebastiano MORENA, Silvano FUMERO, Luca BECCARIA
-
Patent number: 8546547Abstract: The present invention relates to novel polymer conjugates of polypeptide variants of the HMGB1 high affinity binding domain Box-A (HMGB1 Box-A) or of a biologically active fragment of HMGB1 Box-A. Further, the invention relates to novel polymer conjugates of polypeptide variants of the HMGB1 high affinity binding domain Box-A (HMGB1 Box-A). Moreover, the present invention concerns the use of said polymer conjugates of polypeptide molecules of HMGB1 Box-A to diagnose, prevent, alleviate and/or treat pathologies associated with extracellular HMGB1 and/or associated with an increased expression of RAGE.Type: GrantFiled: September 14, 2007Date of Patent: October 1, 2013Assignee: Creabilis Therapeutics S.p.A.Inventors: Silvio Traversa, Chiara Lorenzetto, Valentina Mainero, Sebastiano Morena, Silvano Fumero, Luca Beccaria
-
Patent number: 8518373Abstract: The invention concerns a method for obtaining diagnostic images of a human or animal body organ, region, fluid or tissue by using combined X-ray and/or Magnetization Transfer (MT) based MRI techniques and iodinated radiographic compounds as contrast agents, as well as improved Chemical Exchange dependent Saturation Transfer (CESDT or CEST) based MRI procedures in which a iodinated contrast agents is used for in vivo determining a physiological parameter of diagnostic interest.Type: GrantFiled: December 10, 2009Date of Patent: August 27, 2013Assignee: Bracco Imaging SpAInventors: Silvio Aime, Alessandro Barge, Valentina Mainero, Fulvio Uggeri, Dario Livio Longo, Enzo Terreno, Walter DastrĂ¹
-
Patent number: 8211404Abstract: The invention discloses the use of ionic and non-ionic radiographic contrast agents for combined X-ray and nuclear magnetic resonance (MRI) diagnostics.Type: GrantFiled: July 23, 2002Date of Patent: July 3, 2012Assignee: Bracco Imaging S.p.A.Inventors: Silvio Aime, Alessandro Barge, Valentina Mainero
-
Publication number: 20110311451Abstract: The present invention relates to a process for the preparation of polymer conjugates of i?dolocarbazole compounds, in particular of polymer conjugates of K-252a and derivatives thereof, by a synthetic route which results in a highly pure product, with a high product yield. In a further aspect the present invention relates to novel polymer conjugates of K-252a and derivatives thereof, wherein the chemical group linking the polymer unity to the K-252a or to the K-252a derivative compound is characterised by a 5-member oxazolidindionic cyclic structure.Type: ApplicationFiled: December 22, 2009Publication date: December 22, 2011Applicant: CREABILIS S.A.Inventors: Raffaella Bagnod, Luca Beccaria, Luisa Bertarione Rava Rossa, Domenico Criscuolo, Chiara Lorenzetto, Valentina Mainero, Alessandra Marconi, Carlo Pincelli, Silvio Traversa
-
Publication number: 20100311962Abstract: The invention provides MRI detectable species of formula (I) Dp-Sn-Nm??(I) wherein D is a MRI detectable moiety S is a spacer N is a molecule of a nutrient or pseudo-nutrient n is 0 or an integer m is an integer and p is an integer. These compounds are useful for internalising into tumor cells an amount of the MRI detectable moiety that is distinguishably higher than the amount internalised in normal healthy cells thus allowing the diagnosis of tumors. The internalisation of the MRI detectable moiety involves the nutrients or pseudo-nutrients transporting system. Preferred compounds of formula (I) are those wherein D is the chelated complex of a paramagnetic metal ion.Type: ApplicationFiled: July 2, 2010Publication date: December 9, 2010Inventors: Silvio AIME, Valentina MAINERO, Simonetta Chrich GENINATTI, Claudia CABELLA
-
Patent number: 7780952Abstract: The invention provides MRI detectable species of formula (I): Dp-Sn-Nm, wherein D is a MRI detectable moiety; S is a spacer; N is a molecule of a nutrient or pseudo-nutrient; n is 0 or an integer, m is an integer and p is an integer. These compounds are useful for internalizing into tumor cells an amount of the MRI detectable moiety that is distinguishably higher than the amount internalized in normal healthy cells thus allowing the diagnosis of tumors. The internalization of the MRI detectable moiety involves the nutrients or pseudo-nutrients transporting system. Preferred compounds of formula (I) are those wherein D is the chelated complex of a paramagnetic metal ion.Type: GrantFiled: June 2, 2003Date of Patent: August 24, 2010Assignee: Bracco Imaging SpAInventors: Silvio Aime, Valentina Mainero, Simonetta Chirich Geninatti, Claudia Cabella
-
Publication number: 20100135913Abstract: The invention concerns a method for obtaining diagnostic images of a human or animal body organ, region, fluid or tissue by using combined X-ray and/or Magnetization Transfer (MT) based MRI techniques and iodinated radiographic compounds as contrast agents, as well as improved Chemical Exchange dependent Saturation Transfer (CESDT or CEST) based MRI procedures in which a iodinated contrast agents is used for in vivo determining a physiological parameter of diagnostic interest.Type: ApplicationFiled: December 10, 2009Publication date: June 3, 2010Inventors: Silvio Aime, Alessandro Barge, Valentina Mainero, Fulvio Uggeri, Dario Livio Longo, Enzo Terreno, Walter DastrĂ¹
-
Publication number: 20090324677Abstract: The present invention relates to novel polymer conjugates of polypeptide variants of the HMGB1 high affinity binding domain Box-A (HMGB1 Box-A) or of a biologically active fragment of HMGB1 Box-A. Further, the invention relates to novel polymer conjugates of polypeptide variants of the HMGB1 high affinity binding domain Box-A (HMGB1 Box-A). Moreover, the present invention concerns the use of said polymer conjugates of polypeptide molecules of HMGB1 Box-A to diagnose, prevent, alleviate and/or treat pathologies associated with extracellular HMGB1 and/or associated with an increased expression of RAGE.Type: ApplicationFiled: September 14, 2007Publication date: December 31, 2009Applicant: CREABILIS THERAPEUTICS S.P.A.Inventors: Silvio Traversa, Chiara Lorenzetto, Valentina Mainero, Sebastiano Morena, Silvano Fumero, Luca Beccaria
-
Publication number: 20090191253Abstract: The present invention relates to the use of K-252a, a physiologically active substance produced by microorganisms, and of its salts or synthetic and/or chemically modified derivatives for the prevention or treatment of HMGB1 associated pathologies. More particularly, the present invention relates to the use of K-252a for the prevention or treatment of restenosis.Type: ApplicationFiled: January 29, 2007Publication date: July 30, 2009Applicants: Creabilis Therapeutics S.P.A., Bio3Research srlInventors: Silvano FUMERO, Francesco PILATO, Domenico BARONE, Luisa BERTARIONE RAVA ROSSA, Valentina MAINERO, Silvio TRAVERSA
-
Use of K -252a and Kinase Inhibitors for the Prevention or Treatment of Hmgb1-Associated Pathologies
Publication number: 20080317809Abstract: The present invention relates to the use of K-252a, a physiologically active substance produced by microorganisms, and of its salts or synthetic and/or chemically modified derivatives for the prevention or treatment of HMGB1 associated pathologies. More particularly, the present invention relates to the use of K-252a for the prevention or treatment of restenosis.Type: ApplicationFiled: July 29, 2005Publication date: December 25, 2008Inventors: Silvano Fumero, Francesco P. Pilato, Domenico Barone, Luisa Bertarione Ravarossa, Valentina Mainero, Traversa Silvio -
Publication number: 20080193517Abstract: The present invention relates to novel polymer conjugates of K-252a and derivatives thereof and to their use for the preparation of a pharmaceutical composition useful for the prevention, alleviation and treatment of kinase-associated pathologies. In particular, the present invention relates to the prevention, alleviation and treatment of HMGB1-associated pathologies. In a particular aspect, the invention relates to the use of the novel polymer conjugates of K-252a and derivatives thereof in the preparation of a pharmaceutical composition useful for the prevention, alleviation and treatment of neurological disorders, neuropathies and neurodegenerative disorders of the central and peripheral nervous system.Type: ApplicationFiled: August 25, 2006Publication date: August 14, 2008Applicant: CREABILIS THERAPEUTICS S.P.A.Inventors: Silvio Traversa, Raffaella Bagnod, Domenico Barone, Luisa Bertarione Rava Rossa, Silvano Fumero, Valentina Mainero, Alessandra Marconi, Cecilia Oderda, Carlo Pincelli, Chiara Lorenzetto, Luca Beccaria
-
Publication number: 20050175543Abstract: The invention provides MRI detectable species of formula (I): Dp-Sn-Nm, wherein D is a MRI detectable moiety; S is a spacer; N is a molecule of a nutrient or pseudo-nutrient; n is 0 or an integer, m is an integer and p is an integer. These compounds are useful for internalising into tumor cells an amount of the MRI detectable moiety that is distinguishably higher than the amount internalised in normal healthy cells thus allowing the diagnosis of tumors. The internalisation of the MRI detectable moiety involves the nutrients or pseudo-nutrients transporting system. Preferred compounds of formula (I) are those wherein D is the chelated complex of a paramagnetic metal ion.Type: ApplicationFiled: June 2, 2003Publication date: August 11, 2005Applicant: Bracco Imaging S.p.A.Inventors: Silvio Aime, Valentina Mainero, Simonetta Geninatti, Claudia Cabella
-
Publication number: 20050113675Abstract: The invention discloses the use of ionic and non-ionic radiographic contrast agents for combined X-ray and nuclear magnetic resonance (MRI) diagnostics.Type: ApplicationFiled: July 23, 2002Publication date: May 26, 2005Inventors: Silvio Aime, Alessandro Barge, Valentina Mainero